Profound Medical Q2 FY26 net loss narrows 39% to USD 9.5 million; revenue rises 12% to USD 2.5 million

Reuters2026/08/06 21:11

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Profound Medical Q2 total revenue rose 12% year over year to USD 2.5 million; net loss narrowed 39% to USD 9.5 million (USD 0.26/share).
Gross margin expanded 5 percentage points to 78%; operating expenses fell 16% to USD 13 million.
About USD 3.1 million of TULSA revenue recognition shifted into early Q3 due to shipment timing; Q2 capital equipment sales were USD 871,000.
TULSA-PRO installed base increased to 84; qualified sales pipeline estimated at about USD 70 million.
Full-year 2026 revenue guidance reiterated at about USD 25 million; expects gross margin of 70% or higher.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Profound Medical Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061612PRIMZONEFULLFEED9805646) on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Profound Medical Q2 FY26 net loss narrows 39% to USD 9.5 million; revenue rises 12% to USD 2.5 million

You may also like

Crypto prices